In particular, it is important to examine the ability of PAX5‐C and PAX5 M‐C to cause ALL in vivo and compare the efficacy of HDAC inhibitors for the treatment of ALL developed by them. This evidence concerns the gene HDAC9 and acute lymphoblastic leukemia.